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A key predictor for the success of gene-modified T cell therapies for cancer is the
persistence of transferred cells in the patient. The propensity of less differentiated memory T
cells to expand and survive efficiently has therefore made them attractive candidates for
clinical application. We hypothesized that redirecting T cells to specialized niches in the BM
that support memory differentiation would confer increased therapeutic efficacy. We show
that overexpression of chemokine receptor CXCR4 in CD8+ T cells (TCXCR4) enhanced
their migration toward vascular-associated CXCL12+ cells in the BM and increased their
local engraftment. Increased access of TCXCR4 to the BM microenvironment induced IL-15–
dependent homeostatic expansion and promoted the differentiation of memory precursor–
like cells with low expression of programmed death-1, resistance to apoptosis, and a
heightened capacity to generate polyfunctional cytokine-producing effector cells. Following
transfer to lymphoma-bearing mice, TCXCR4 showed a greater capacity for effector
expansion and better tumor protection, the latter being independent of changes in trafficking
to the tumor bed or local out-competition of regulatory T cells. Thus, redirected homing of T
cells to the BM confers increased memory differentiation and antitumor immunity,
suggesting an innovative solution to increase the persistence and functions of therapeutic T
cells.
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Introduction
The effector functions of T cells can be redirected against tumor 
antigens by gene transfer of T cell receptors (TCRs) or chimeric 
antigen receptors (CARs) to create large numbers of tumor-reac-
tive cells for adoptive transfer. Early-phase clinical trials of anti-
tumor T cells have shown significant efficacy in certain tumors 
(e.g., the use of anti-CD19 CAR-T cells for the treatment of acute 
lymphoblastic leukemia), and several parameters have emerged 
that predict response; these include the number of cells infused, 
their replicative potential, and their in vivo persistence follow-
ing transfer (1–9). Host factors — for example, the peak levels of 
IL-15, a homeostatic cytokine that supports T cell proliferation 
and survival — also appear important (10, 11). In animal models, 
it has been shown that less differentiated T cells show greater in 
vivo expansion and survival than fully differentiated effector cells 
(12), a finding that relates to the former’s greater capacity for self-
renewal. According to the progressive model of memory T cell 
formation, memory stem cells (Tscm)and central memory cells 
(Tcm) are less differentiated T cells that can divide to self-renew 
as well as generate more differentiated effector cells (13). There 
has therefore been interest in developing methods to generate and 
expand Tscm and Tcm in order to increase efficacy of therapeutic 
T cells. Current experimental strategies aim to transiently restrict 
terminal differentiation following T cell activation, for example 
by modifying use of metabolic pathways (14), activating Wnt– 
β-catenin (15), inhibiting Akt-mTOR (16, 17), or exposing cells to 
the homeostatic cytokines IL-15 and IL-7 (18).
An alternative approach is to identify and exploit anatomical 
niches that potentiate the expansion of Tscm and Tcm. The bone 
marrow (BM) is one site that may potentially contain such special-
ized microenvironments, and it has been hypothesized that, akin 
to hematopoietic stem cells, memory T cells may reside in distinct 
niches that support quiescence or proliferation and, critically, self-
renewal (19). As early as 3 days after infection, memory precursor 
CD8+ T cells that are quiescent relative to the bulk effector popula-
tion locate preferentially in the BM (20). In humans, a quiescent 
subset of memory T cells characterized by high ATP-binding cas-
sette (ABC) transporter expression is also enriched in the BM (21). 
Recent studies have shown that exclusion from or displacement to 
the BM can have profound effects on the generation and/or sur-
vival of memory T cells. For example, Tcm are characterized by 
higher surface expression of CXCR4 than other T cell subsets and 
preferentially recirculate to the BM in response to CXCL12 (22). 
CXCR4 is required for integrin activation and memory CD8+ T 
cell adhesion in BM microvessels (22); in its absence, Tcm show a 
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expression is shown Supplemental Figure 2), we also examined 
whether TCXCR4 would similarly outcompete control cells in the BM 
of nonirradiated Rag1-knockout (Rag1ko) mice. As demonstrated 
in Figure 1E, TCXCR4 showed a similar propensity for BM accumula-
tion on day 7 following transfer to B6 mice pretreated with 5.5 Gy 
total-body irradiation and untreated Rag1ko mice, indicating that 
the competitive advantage of TCXCR4 in the BM was independent of 
direct effects of irradiation. Irradiation did, however, have a minor 
but significant impact in mitigating the reduced relative accumu-
lation of TCXCR4 in the spleen and LN.
We hypothesized that T cells entering the BM with greater 
efficiency would be able to better access local niche elements that 
promote their proliferation and/or survival. If greater competition 
for niche-related factors or cells contributed to the increased accu-
mulation of TCXCR4 in the BM over control cells, we reasoned that 
such an advantage would be enhanced under conditions in which 
such factors were limiting. In the same series of experiments as 
shown in Figure 1B, we therefore compared the distribution of 
TCXCR4 and TControl in competitive experiments under lymphocyte-
replete (untreated B6 mice) versus lymphocyte-deficient (Rag1ko 
mice) conditions, the former condition exposing infused T cells to 
greater competition with endogenous T cells. These experiments 
showed that the ratio of TCXCR4/TControl at day 7 following transfer 
was about 4-fold greater in the BM of nonirradiated WT com-
pared with Rag1ko mice (Figure 1F). These data suggested that 
the skewed distribution of TCXCR4 to the BM was most pronounced 
under conditions in which CD8+ T cells have to compete with other 
lymphoid cells for niche factors or cells supporting their survival 
and/or proliferation. Because CD8+ T cells compete for homeo-
static cytokines, we determined whether access to either IL-15 or 
IL-7 influenced the redistribution of TCXCR4 to the BM. In evaluat-
ing the role of IL-15, we used recipient mice that lacked expres-
sion of IL-15 receptor α (IL-15Rα); in this case, host cells are unable 
to trans-present IL-15 via cell surface IL-15Rα, leading to a func-
tional deficiency of IL-15 (11). For these experiments, we therefore 
injected an equal mix of polyclonal B6 TCXCR4 (CD45.1) and TControl 
(Thy1.1) to Rag1ko mice or Rag1ko mice lacking IL-7 or IL-15Rα 
before evaluating relative accumulation on day 7. As shown in Fig-
ure 1G, the capacity of TCXCR4 to outcompete TControl in the BM was 
dependent on host expression of IL-15Rα, whereas the absence of 
IL-7 had no significant effect; the dependence on IL-15Rα was spe-
cific to the BM at this early time point with no differences observed 
between the groups in the LN or spleen.
TCXCR4 show increased migration toward BM CXCL12+ cells. To 
determine the respective behaviors of TCXCR4 versus TControl in the 
BM, we performed intravital calvarial BM imaging following sepa-
rate injection of transduced cells into nonirradiated Rag1ko mice; in 
each case, the GFP reporter was used to track the transduced cells. 
We used a tile-based imaging approach that permitted tissue-wide 
visualization of BM structures while maintaining a resolution per-
mitting measurement of interactions with BM cells by time-lapse 
microscopy (Figure 2A). Recipient mice received i.v. injection of 
anti-CXCL12 phycoerythrin-conjugated (PE-conjugated) anti-
body 15 minutes before imaging to reveal CXCL12+ cells associated 
with the vasculature (identified by concurrent injection of Cy5- 
dextran). In separate experiments using Flk1-Gfp reporter mice to 
identify endothelial cells in relation to CXCL12 staining, we found 
reduced frequency in BM and deficits in self-renewal in response to 
homeostatic signals, although effector responses following antigen 
challenge are largely intact (23). A corollary of this is that absence 
of CCR7 expression in memory T cells leads to their displacement 
from lymph nodes to the BM, where they undergo enhanced IL-15–
dependent expansion (24). Although T cell–specific niche-organiz-
ing cells in the BM have not yet been identified at high resolution, 
memory T cells can be found in close proximity to cells producing 
IL-15 or VCAM-1–expressing stromal cells expressing other mol-
ecules that could be important in promoting their survival and/or 
proliferation, including IL-7 and 4-1BBL (25–27).
In this study, we tested the hypothesis that overexpression of 
CXCR4 in therapeutic CD8+ T cells would improve their functions 
and antitumor efficacy by directing them to memory niches in the 
BM. We demonstrate that CXCR4 overexpression redistributes 
engrafting cells to the BM, where they migrate toward CXCL12-
expressing cells associated with the vasculature. Following antigen 
activation, increased access to IL-15 in the BM microenvironment 
drives enhanced expansion of the modified T cells and promotes 
their differentiation into early memory-like cells with greater anti-
tumor functions. Thus, CXCR4 overexpression in therapeutic T 
cells is a potential platform technology to increase the persistence 
and function following adoptive transfer.
Results
Adoptively transferred CD8+ T cells overexpressing CXCR4 are pref-
erentially recruited to the BM. To determine whether increasing 
CXCR4 surface expression in murine T cells would influence 
their distribution, we transduced polyclonal CD8+ T cells from 
C57BL/6 (B6) mice with a modified pMP71 retroviral vector con-
taining murine Cxcr4 and Gfp reporter sequences (TCXCR4) or with 
a control vector containing Gfp alone (TControl). As shown in Figure 
1A and Supplemental Figure 1 (supplemental material available 
online with this article; https://doi.org/10.1172/JCI97454DS1), 
both untreated CD8+ T cells and TControl expressed a low level of cell 
surface CXCR4. Compared with GFP+ TControl, GFP+ TCXCR4 showed 
a median of 11.3-fold increase in CXCR4 expression (range 2.2–
41.2, P = 0.03; Wilcoxon signed-rank test against a hypothetical 
ratio of 1.0). We then injected an equal mix of TCXCR4 (derived from 
B6 CD45.1 congenic mice) and TControl (derived from B6 Thy1.1 
mice) into B6 hosts (CD45.2, Thy1.2) receiving sublethal irradia-
tion and used the respective congenic markers to measure the rel-
ative numbers of each transferred population in the BM, peripher-
al lymph node (LN), and spleen. At 3 hours, the initial engraftment 
of each transduced T cell population at each site was equivalent as 
indicated by a TCXCR4/TControl ratio close to 1.0 (ratio 1.0 indicated 
by dotted line; Figure 1C). However, by 24 hours TCXCR4 accumula-
tion in the BM was 2- to 3-fold greater than TControl accumulation, 
whereas accumulation in the peripheral LN and spleen was mod-
erately reduced. Seven days after transfer, the preferential redis-
tribution of TCXCR4 to the BM had increased to 3- to 4-fold over 
controls (Figure 1, B and C). The pattern of increased distribution 
of TCXCR4 to the BM and away from the LN was also found under 
noncompetitive conditions in which each transduced T cell pop-
ulation was transferred to separate irradiated mice (Figure 1D). 
Because irradiation of the BM can disrupt the sinusoidal struc-
ture and increase local expression of CXCL12 (28) (Cxcl12 mRNA 
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without adhering to the vasculature or entering the BM parenchy-
ma were not included in our analysis. Frequently, cells within both 
the TCXCR4 and TControl populations appeared to transiently scan the 
surface of vasculature-associated CXCL12+ cells. We also noted 
substantial heterogeneity in TCXCR4 behavior, with some cells mov-
ing very quickly in extravascular areas, whereas other cells with a 
rounder shape (cells sticking or rolling on the intraluminal surface 
of vessels or within the BM parenchyma) moved more slowly. To 
that in vivo–labeled, vasculature-associated CXCL12+ cells were 
both Flk1+ and Flk1– (Supplemental Figure 3). As shown in Figure 2A, 
TCXCR4 were far more numerous than TControl and tended to be local-
ized in loose clusters of cells rather than distributed evenly as indi-
vidual cells throughout the BM space. To determine how CXCR4 
overexpression affected the movement of T cells within the BM, we 
used time-lapse microscopy to track individual cells (Supplemen-
tal Videos 1–4). Cells moving very quickly through the circulation 
Figure 1. Adoptively transferred TCXCR4 demonstrate superior recruitment to the BM. (A) Representative flow cytometry plots for CXCR4 expression in 
untreated CD8+ T cells (unstimulated), TControl, or TCXCR4. Gating based on “fluorescence minus 1” controls. CXCR4 median fluorescence index (MFI): 380 
unstimulated; 587 GFP+ TControl; 2,409 GFP+ TCXCR4. (B and C) Equal mixtures of TCXCR4 (CD45.1+) and TControl (Thy1.1+) were injected into sublethally irradiated B6 
mice. Representative plots of TCXCR4 (red) and TControl (blue) frequencies in BM, spleen (Sp), and LN at day 7 are shown in B. Summary graphs in C indicate 
mean ± SD TCXCR4/TControl ratio at timed intervals in BM, Sp, and LN (n = 6 per group at 3 and 24 hours, n = 4 per group at day 7). Statistical comparison was 
performed by Wilcoxon’s signed-rank test against a hypothetical ratio of 1.0 (dotted line). *P ≤ 0.05. (D) Box-and-whisker graphs for BM/LN ratio on day 
14 following transfer of TCXCR4 or TControl to separate sublethally irradiated B6 mice, calculated by division of percent GFP+ of BM CD8+ T cells by percent GFP+ 
of LN CD8+ T cells (n = 6 TCXCR4, n = 5 TControl). (E) Box-and-whisker graphs of TCXCR4/TControl ratio in BM, Sp, and LN at day 7 following transfer into sublethally 
irradiated B6 mice (n = 4) and untreated Rag1ko mice (n = 10). (F) Box-and-whisker graphs of TCXCR4/TControl ratio in BM, Sp, and LN at day 7 following transfer 
into untreated B6 mice (n = 11) and untreated Rag1ko mice (n = 10). (G) Box-and-whisker graphs of ratio of TCXCR4/TControl in BM, Sp, and LN at day 7 following 
transfer into Rag1ko (n = 10), Rag1ko.Il15rako (n = 10), and Rag1ko.Il7ko (n = 4). Statistical comparisons in D and E were made using the Mann-Whitney test 
(2-tailed). *P ≤ 0.05, **P ≤ 0.01. All data are pooled from 2–3 independent experiments.
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associated CXCL12+ staining. However, when we compared the 
entire GFP+ TCXCR4 versus TControl populations, we found no differ-
ence between the groups (the TCXCR4 median distance to nearest 
CXCL12+ cell was 6.9 μm [range 0.3–64.8], whereas the TControl 
median distance was 8.5 μm [range 0.3–73.4], P = NS). We reasoned 
that migration of TCXCR4 and proximity to CXCL12-producing cells 
might depend on the level of CXCR4 expression by individual cells. 
We therefore re-evaluated cell position of TCXCR4 and TControl popula-
tions according to the expression level of the GFP reporter (which 
is proportionate to CXCR4 in TCXCR4 cells; see Figure 1B). As shown 
in Figure 2D, there was an inverse correlation between distance 
to CXCL12+ cells and GFP expression for TCXCR4 but not for TControl. 
Thus, CXCR4 overexpression in CD8+ T cells enhances their motil-
ity and directed migration toward vascular-associated CXCL12+ 
cells in the BM.
TCXCR4 show enhanced memory precursor differentiation and 
function. To test how CXCR4 overexpression would affect the 
define whether cells were moving predominantly or “pausing,” we 
characterized T cell behavior according to their arrest coefficients 
(defined as the proportion of time a cell’s instantaneous velocity 
was ≤2 μm/min). The TControl group showed a tendency toward cells 
with high arrest coefficients (that is, cells were moving more slowly 
than 2 μm/min for the majority of the time). In contrast, the TCXCR4 
population showed a clear bimodal distribution for arrest coeffi-
cient with a significant subset of cells with lower values (Figure 2B). 
Consistent with the concept that TCXCR4 contained a subset of cells 
that were more motile than TControl, their mean velocity was higher 
than that of TControl (mean velocity 3.9 ± 3.3 μm/min vs. 2.2 ± 1.6 μm/
min, P = 0.004; Figure 2C). Increased motility of TCXCR4 compared 
with controls could potentially relate to higher chemokinesis and/
or chemotaxis. To assess whether the increased motility of TCXCR4 
was consistent with greater chemotaxis toward CXCL12-produc-
ing cells than TControl, we analyzed the tiled image data to measure 
the distance between GFP+ T cells from each group and vascular-
Figure 2. TCXCR4 show enhanced motility and directed migration to vascular-associated CXCL12+ cells in BM. (A) Left: Diagram showing strategy for 
calvarial imaging. Right: Intravital confocal calvarial imaging of transduced T cells (green) was performed 8 weeks after injection of TControl and TCXCR4 into 
separate Rag1ko mice. Representative maximum projection tile scans and corresponding high-magnification insets are shown following i.v. injection of 
anti-CXCL12–PE (red) and Cy5-dextran to identify vasculature (blue). Scale bars: 500 μm in low-magnification images, 50 μm in inset images. (B) Summary 
graph showing arrest coefficient data for time-lapse imaging of TControl and TCXCR4. Data are pooled from 5 mice (n = 2 TControl and n = 3 TCXCR4). Median track-
ing period was 8.5 min/cell, range 8.5–30 min/cell (total number of cells tracked n = 72 TCXCR4, n = 16 TControl). (C) Summary graph showing mean velocity of 
tracked cells. Statistical comparison was made using a t test (2-tailed). **P ≤ 0.01. (D) X-y graphs showing GFP intensity (x axis) versus distance (y axis) of 
individual TControl (n = 54, left) and TCXCR4 (n = 108, right) from CXCL12+ cells measured on static images derived from the same experiments in A–C. Inset to 
each graph shows Pearson’s correlation coefficient r and significance value.
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similar pattern in the Ag+ group but with a nonsignificant trend for 
lower ratios than in the no-Ag group (day 36; in BM, mean ratio 
119.4 ± 106.9 no Ag, 15.2 ± 6.5 Ag+; in spleen, mean ratio 53.8 ± 
58.0 no Ag, 9.0 ± 15.0 Ag+). These data are therefore consistent 
with a model in which homeostatic rather than Ag-driven signals 
are responsible for the OT-I TCXCR4 outcompeting OT-I TControl in the 
BM. The finding that the competitive advantage for OT-I TCXCR4 
is initially observed only in the BM but then, later, extends to the 
spleen suggests a 2-phase model in which CXCR4 overexpression 
first increases T cell trafficking to the BM and, second, leads to 
the enhanced expansion and engraftment of cells that can recir-
culate to other lymphoid organs. Consistent with this concept, in 
an independent vaccination experiment, OT-I TCXCR4 had an initial 
competitive disadvantage in the peripheral blood for 28 days fol-
lowing vaccination (with a nadir at day 14, median ratio 0.6, range 
functions of antigen-activated (Ag-activated) CD8+ T cells, we 
transduced murine OT-I cells (from either a CD45.1 or a CD45.2 
background) with the Cxcr4 or control retroviral constructs and 
then transferred them at a 1:1 ratio to Rag1ko mice (Figure 3). To 
test responses to Ag, we used a prime-boost schedule in which a 
cohort of mice were vaccinated s.c. with ovalbumin peptide (SIIN-
FEKL) and incomplete Freund’s adjuvant (IFA) on day +1 follow-
ing transfer and again on day +29 (Ag+ group), whereas controls 
were vaccinated with irrelevant peptide and IFA (no-Ag group). As 
shown in Figure 3A, the OT-I TCXCR4/OT-I TControl ratio in the no-Ag 
group showed an initial competitive advantage for OT-I TCXCR4 in 
the BM (day +8, mean ratio 51.5 ± 35.5). At later time points (day 
+28 and day +36), OT-I TCXCR4 had extensively outcompeted con-
trol cells in both the BM and spleen, whereas in the LN they were 
similar in number. The OT-I TCXCR4/OT-I TControl ratios followed a 
Figure 3. Ag-activated TCXCR4 retain a CD62Lhi phenotype. Equal numbers of OT-I TCXCR4 and TControl were coinjected into Rag1ko mice, before prime-boost 
vaccination with relevant SIINFEKL peptide plus IFA (Antigen, n = 17) or irrelevant peptide plus IFA (No antigen, n = 8) on days 1 and 29. Tissues were har-
vested on day 8 (n = 4 per group), 29 (n = 3 Ag, n = 1 no Ag), and 36 (n = 9 Ag, n = 3 no Ag). Data from 4 independent experiments (with the exception of 
day 29 no-Ag group derived from 1 experiment). (A) Summary (mean ± SD) TCXCR4/TControl in BM, Sp, and LN over time for no-Ag (circles, dashed lines) and 
Ag groups (squares, solid line). Arrows indicate time of prime-boost vaccination. (B) Summary (mean ± SD) CD62L expression over time in TCXCR4 (red) and 
TControl (blue) in no-Ag (left) and Ag groups (right). (C) Representative plots for TCXCR4 and TControl accumulation and surface expression of CD44 and CD62L 
on day 36 in BM, Sp, and LN. Numbers denote frequencies of TCXCR4 (red), TControl (blue), and proportions of CD62Lhi and CD62Llo cells (black). (D) Box-and-
whisker graphs showing summary of TCXCR4/TControl ratios in BM, Sp, and LN on day 36 following transfer into Rag1ko (Il15ra WT, n = 9) and Rag1ko.Il15rako 
(Il15rako, n = 6) mice undergoing the same prime-boost vaccination schedule outlined in A. Data derived from 3 independent experiments. (E) Box-and-
whisker graphs showing summary data for CD62L expression by TControl or TCXCR4 on day 36 in the same experiments outlined in D. In A and D, statistical 
comparisons were made by Wilcoxon’s signed-rank test against a hypothetical ratio of 1.0 (dotted line). *P ≤ 0.05, **P ≤ 0.01. In B, C, and E, statistical 
comparisons were made using the Mann-Whitney test (2-tailed). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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0.3–0.8), before demonstrating a later competitive advantage at 
this location on day 90 (median ratio 2.9, range 1.7–6.4, in blood; 
median 39.8, range 37.1–130.5, in BM; Supplemental Figure 4).
We next asked whether overexpression of CXCR4 would con-
fer additional phenotypic or functional properties to CD8+ T cells 
responding to Ag. We first evaluated transduced T cells in mice 
immunized in the Ag+ and no-Ag groups for surface expression of 
CD62L, a cell adhesion molecule that is shed upon effector differ-
entiation. In response to Ag challenge, the majority of OT-I TControl 
showed reduced CD62L expression in all compartments, but espe-
cially the BM and spleen, consistent with differentiation to effec-
tor or effector memory cells, whereas in the no-Ag group TControl 
remained CD62Lhi. In sharp contrast, although there was some 
reduction in CD62L expression in comparison with the no-Ag 
group, the OT-I TCXCR4 population from Ag-exposed mice retained 
greater CD62L expression than OT-I TControl at all sites tested (Fig-
ure 3, B and C). For example, in the BM the mean proportion of 
OT-I TCXCR4 with a CD62Lhi phenotype at day 36 was 64% versus 
23% for OT-I TControl. Although the proportion of CD62Llo effec-
tor cells was lower for the OT-I TCXCR4 population than controls, 
their absolute number was in fact higher in the BM at day 36 and 
equivalent in the LN and spleen (Supplemental Figure 5), a find-
ing consistent with the greater expansion of the entire population; 
these data indicate that OT-I TCXCR4 are proficient in generating 
effector-like cells but that there is a shift in the overall repertoire 
to include a greater frequency of less differentiated cells. We con-
sidered the possibility that the shift toward a CD62Lhi phenotype 
in Ag-activated OT-I TCXCR4 following the s.c. vaccination protocol 
we had used occurred as a result of their redistribution away from 
LN to the BM; in this circumstance, some T cells might receive 
less antigenic stimulation. Thus, we rerouted vaccination by using 
peptide-pulsed CD11c+ DCs intravenously, a method that seeds 
DCs to the spleen and BM but not LN (29). As shown in Supple-
mental Figure 6, OT-I TCXCR4 still had a competitive advantage in 
the BM and retained greater CD62L expression than OT-I TControl 
in all compartments. To determine whether increased competition 
for an IL-15Rα+ niche in the BM could explain the greater expansion 
of CD62Lhi OT-I TCXCR4 in response to Ag, we compared the day 36 
responses of OT-I TCXCR4 versus control cells in Rag1ko.Il15ra WT 
or Rag1ko.Il15rako recipient mice. As shown in Figure 3, D and E, 
the presence of IL-15α in the host was necessary for OT-I TCXCR4 to 
outcompete control cells in the BM, whereas this was not the case 
in the spleen or LN. The enhanced retention of CD62L expression 
by OT-I TCXCR4 following Ag exposure was also dependent on host 
IL-15α expression in the BM and spleen, with a similar trend in the 
LN. We noted slightly higher expression of CD62L by OT-I TCXCR4 
in the BM and LN even in the absence of host IL-15α expression; 
this suggests that CD62L expression in OT-I TCXCR4 is also regulated 
to a minor extent by a mechanism independent of host IL-15α.
Because a CD62Lhi phenotype of Ag-activated T cells is asso-
ciated with greater memory differentiation (13), we also evalu-
ated Ag-activated OT-I TCXCR4 and TControl in the BM for other 
phenotypic and functional properties that mark memory cells. 
At day 36 following vaccination, the OT-I TCXCR4 population was 
characterized by higher surface expression of IL-15Rβ (CD122), a 
receptor that is highly expressed on memory phenotype cells and 
is required for responsiveness to trans-presented IL-15 (11). In 
addition, OT-I TCXCR4 had higher intracellular expression of Bcl2, 
an antiapoptotic molecule that is also upregulated in memory 
cells (Figure 4, A and B). The CD62LhiBcl2hi profile was positively 
correlated with the level of CXCR4 expression as inferred from 
the intensity of GFP reporter fluorescence (Figure 4, C and D). 
To determine the proliferative response of transduced T cells fol-
lowing Ag exposure, we administered 5-ethynyl-2′-deoxyuridine 
(EdU) to mice by i.p. injection at timed intervals following vac-
cination and evaluated its incorporation 24 hours later. The pro-
liferative burst of T cells in response to Ag was blunted in OT-I 
TCXCR4 compared with OT-I TControl following both the prime and 
the boost vaccination (Supplemental Figure 7 and Figure 4, A and 
B). However, consistent with their greater expansion than control 
cells and higher expression of Bcl2, OT-I TCXCR4 had reduced lev-
els of apoptosis as measured by staining for activated caspase-3 
(Figure 4, A and B). Because these data were consistent with OT-I 
TCXCR4 possessing a “less differentiated” memory phenotype com-
pared with controls (13), we also evaluated the expression of other 
markers that delineate different stages of differentiation in T cells 
responding to Ag. In T cells isolated from the spleen at day 36 (to 
allow a greater number of comparisons with control cells, which 
were limiting in the BM), the OT-I TCXCR4 population showed 
reduced frequencies of cells with a terminally differentiated state 
(Figure 4, E and F). Thus, compared with controls, OT-I TCXCR4 
contained lower frequencies of cells that were KLRG-1hiCD127lo 
(a phenotype of short-lived effector cells) but reciprocally higher 
frequencies of cells that were KLRG-1loCD127hi (memory precur-
sor effector cells [MPECs]) (30). Furthermore, the OT-I TCXCR4 
population contained fewer cells that were dual-positive for the 
coinhibitory receptor programmed death-1 (PD-1) and the T-box 
transcription factor eomesodermin, a profile that is associated 
with a terminally differentiated, exhausted state (31). The above 
phenotypic and functional differences between OT-I TCXCR4 and 
OT-I TControl were observed only in Ag+ mice, with no significant 
differences observed in no-Ag controls (data not shown).
To test the functional properties of transduced T cells, we iso-
lated OT-I TCXCR4 and OT-I TControl from the spleens of mice on day 
+36 and restimulated cells with relevant and irrelevant peptide 
over 4 hours ex vivo. OT-I TCXCR4 demonstrated enhanced effector 
IFN-γ, TNF-α, and IL-2 cytokine generation in response to ex vivo 
stimulation (Figure 5, A and B). Furthermore, by applying Bool-
ean gating strategy, we detected an increase in the frequency of 
polyfunctional T cells among the OT-I TCXCR4 population (mean 
percentage of cells expressing 2 or more cytokines, 21.3% ± 6.2% 
for OT-I TCXCR4 vs. 8.7% ± 6.1% for OT-I TControl, P < 0.001; Figure 
5C). Because CXCL12 binding is reported to amplify TCR signal-
ing and function in T cells (32), we also determined the effect of 
exposure to recombinant CXCL12 on memory phenotype or cyto-
kine generation of freshly transduced OT-I TCXCR4 and OT-I TControl 
following TCR activation in vitro. As shown in Figure 5, D and E, 
CXCL12 had no effect on either CD62L expression or cytokine 
generation of OT-I TCXCR4 and OT-I TControl populations. Similar 
results were observed following titration of the concentration of 
CXCL12. Taken together with the data shown in Figures 3 and 4, 
the discrepancy between in vitro and in vivo phenotype indicates 
that the effect of CXCR4 overexpression on T cells relates to how 
it affects migration and exposure to environmental cues.
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Resting memory TCXCR4 possess a less differentiated memory sig-
nature. To determine how enhanced CXCR4 expression affected 
memory T cell differentiation at the transcriptional level, we 
transferred OT-I TCXCR4 or OT-I TControl to mice that were then vac-
cinated with peptide-pulsed DCs. Resting memory OT-I TCXCR4 or 
OT-I TControl were then isolated from the spleen 90 days after DC 
vaccination, and gene expression profiling was performed. By this 
stage, OT-I TCXCR4 outnumbered controls at all sites (44.8 ± 40.1–
fold in BM, 7.3 ± 3.1–fold in spleen, and 6.9 ± 3.3–fold in LN; data 
not shown) and had maintained a higher proportion of CD62Lhi 
cells at all sites (e.g., spleen, percentage CD62Lhi 93.2% ± 1.6% 
OT-I TCXCR4 vs. 73.5% ± 4.5% OT-I TControl; data not shown). Using 
a cutoff of ≥1.5-fold differential gene expression and a P value less 
than or equal to 0.01, 414 genes were upregulated in TCXCR4 com-
pared with control cells and 63 genes were downregulated (Sup-
plemental Table 1 and Figure 6A). Several genes upregulated in 
TCXCR4 or their related pathways have previously been implicated in 
promoting T cell memory differentiation or survival; these includ-
ed Cpt1a, encoding an IL-15–regulated mitochondrial protein 
required for fatty acid oxidation in MPECs (33); the TNF super-
family ligand Tnfsf14 (34); several genes associated with the Wnt 
pathway (e.g., Ppp2cb) (15) or TGF-β signaling (e.g., Tggb1, Smad3) 
(35); and the chemokine receptor genes Cxcr3 (36) and Cxcr6 (37). 
Other upregulated genes were linked to attenuation of TCR acti-
vation (e.g., Ptpn11, encoding the SHP2 phosphatase [ref. 38], and 
Cbl, encoding an E3 ubiquitin ligase [ref. 39]), a process that could 
be important in preventing terminal differentiation. The expres-
sion of several Toll-like receptor (TLR) genes was also increased 
in TCXCR4 (Tlr3, Tlr6, and Tlr7), although the role of direct TLR sig-
naling in memory T cell function is less clear (40). Consistent with 
memory TCXCR4 maintaining a less differentiated state, genes with 
reduced expression compared with controls were those associated 
Figure 4. Ag-activated TCXCR4 adopt a less differentiated memory phenotype. Equal numbers of OT-I TCXCR4 and TControl were coinjected into Rag1ko mice, 
which then underwent prime-boost vaccination with relevant SIINFEKL peptide plus IFA on days 1 and 29. Tissues were harvested on day 36 (n = 9); data are 
pooled from 4 independent experiments. (A and B) Representative flow cytometric histograms (A) and summary data (B) for expression of surface IL-15Rβ 
(CD122), intracellular Bcl2, EdU incorporation, and caspase-3 activity in TControl (blue) versus TCXCR4 (red) on day 36 in cells isolated from the BM. Statistical sig-
nificance was tested using Wilcoxon’s ranked-sum test (2-tailed). *P ≤ 0.05, **P ≤ 0.01. (C and D) Representative flow cytometric histograms (C) and sum-
mary data (mean ± SD) (D) for CD62L and Bcl2 staining in BM TCXCR4 gated according to GFP reporter expression (gates 1–4).Numbers shown as insets of the 
flow cytometric histograms relate to CD62L median fluorescence index (MFI) and proportion of Bcl2+ cells in the gated subset. Statistical significance was 
tested using the Mann-Whitney test (2-tailed). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (E and F) Representative flow cytometric contour plots (E) and summary 
data (F) for frequency of splenic TControl (blue) and TCXCR4 (red) with short-lived effector cell (SLEC) (KLRG-1hiCD127lo), MPEC (KLRG-1loCD127hi), and exhausted 
(PD-1hiEomeshi) phenotypes on day 36 (n = 5). Statistical significance was tested using Wilcoxon’s ranked-sum test (2-tailed). *P ≤ 0.05.
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and VII (memory precursors) as compared with controls. Notably, 
gene clusters IV and VII are also both enriched in MPECs that can 
be identified at the initiation of a CD8+ T cell response to Ag (30). As 
shown in Figure 6D, TCXCR4 showed enrichment for published gene 
signatures of MPECs identified on the basis of surface markers 
(CD127hiKLRG-1lo) (43). Finally, consistent with the requirement 
for IL-15 trans-presentation for the enhanced expansion of TCXCR4, 
we also found enrichment for a memory stem cell–like signature 
that is induced in human T cells gene-modified for constitutive sig-
naling via a tethered IL-15–IL-15Rα complex (44) (Figure 6D).
TCXCR4 demonstrate enhanced antitumor efficacy. Taken togeth-
er, the data in Figures 3–6 show that redirection of CD8+ T cells to 
the BM confers increased differentiation of memory precursor– 
like cells with greater potential for expansion and function. To 
examine how CXCR4 overexpression would impact on antitu-
mor immunity, we evaluated graft-versus-tumor (GvT) responses 
mediated by allogeneic (B6, H-2b) T cells following transfer to 
tumor-bearing BALB/c (H-2d) recipients. Thus, BALB/c recipient 
mice received lethal irradiation followed on day 0 by i.v. infusion 
of T cell–depleted B6 BM and s.c. injection of 5 × 106 host-strain 
B cell lymphoma, A20 (H-2d). Two days later, 1 × 106 B6-derived 
with cellular activation (e.g., Ilr2a, Itga4) and several genes encod-
ing molecules associated with cellular cytotoxicity (e.g., Klrk1, 
Klrc1, Gzmk, Gzmb, and Fas). A gene set enrichment analysis using 
the Reactome database collection is represented in Figure 6B as 
an enrichment map, showing the pathways differentially enriched 
in TCXCR4 versus TControl (see Supplemental Table 2 for complete list 
of enriched pathways). Memory TCXCR4 were enriched for gene 
sets relating to mitosis and cell cycle, metabolic functions, RNA 
processing and transcription, Wnt signaling, signal transduction 
(through MAPK/ERK, stem cell factor/Kit, EGFR, or TLR), and 
IFN-γ signaling. In contrast, gene sets related to signaling via G 
protein–coupled receptors (GPCRs) were downregulated in mem-
ory TCXCR4; since CXCR4 is a GPCR, this finding is consistent with 
receptor desensitization following continual stimulation (41).
To better align the transcriptional profiles of TCXCR4 to specific 
T cell differentiation states, we next compared our data with a pub-
lished set of 10 gene clusters that segregate with specific phases of 
an in vivo OT-I response to Ag (42). As shown in the BubbleGUM plot 
(http://www.ciml.univ-mrs.fr/applications/BubbleGUM/index. 
html) in Figure 6C, TCXCR4 were primarily enriched for gene clus-
ters II (preparation for cell division), IV (naive and late memory), 
Figure 5. Ag-activated TCXCR4 have increased potential for polyfunctional cytokine generation. Equal numbers of OT-I TCXCR4 and OT-I TControl were coinjected 
into Rag1ko mice, which then underwent prime-boost vaccination with relevant SIINFEKL peptide plus IFA on days 1 and 29. T cells were isolated from the 
spleen on day 36 (n = 7). (A) Representative flow cytometric contour plots showing IFN-γ and TNF-α intracellular costaining in OT-I TCXCR4 and OT-I TControl 
after ex vivo stimulation with relevant peptide with gates set according to stimulation with irrelevant peptide. (B) Summary data for IFN-γ, TNF-α, and IL-2 
generation from OT-I TControl (blue) and OT-I TCXCR4 (red) in the same assays. Statistical significance tested using the Wilcoxon ranked sum test (two-tailed), 
*P ≤ 0.05, **P ≤ 0.01. (C) Pie charts depicting polyfunctional cytokine generation in TControl and TCXCR4 according to Boolean combination gates identifying 
IFN-γ+, TNF-α+, and IL-2+ cells. (D) Transduced OT-I TCXCR4 and OT-I TControl were stimulated in vitro with relevant or irrelevant peptide and in the absence or 
presence of 500 ng/ml of recombinant murine CXCL12. Representative flow cytometric contour plots showing CD44 and CD62L surface expression. Data 
shown are representative of 2 independent experiments. (E) Summary data (mean ± SD) for intracellular IFN-γ generation after in vitro stimulation with 
anti-CD3 in the presence or absence of CXCL12 (n = 3 from 3 independent experiments).
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Figure 6. Resting memory TCXCR4 possess a memory precursor–like signature. (A) Heatmap showing the relative expression levels of the genes differentially 
expressed between resting memory OT-I TCXCR4 and controls (fold change ≥1.5, P ≤ 0.01); labels identify specific genes as discussed in the text. (B) The net-
work map displays the Reactome gene sets enriched in OT-I TCXCR4 versus OT-I TControl. Node area indicates the size of the gene set; color code reflects enrich-
ment in OT-I TCXCR4 (red) or OT-I TControl (blue); color intensity is proportional to statistical significance. Clusters of functionally related gene sets were manually 
circled and assigned a label. NES, normalized enrichment score. (C) Gene set enrichment analysis–based (GSEA-based) assessment of the stage of antigenic 
response of OT-I TCXCR4 and OT-I TControl according to the 10 phase-specific gene sets identified by Best et al. (42). Results are represented in a BubbleGUM plot, 
in which stronger and more significant enrichments are represented by larger and darker bubbles, colored red for OT-I TCXCR4 or blue for OT-I TControl. (D) GSEA 
plots showing that memory OT-I TCXCR4 upregulate genes associated with early memory cells and with increased responsiveness to IL-15.
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Figure 7. TCXCR4 demonstrate enhanced tumor protection. All mice underwent B6→BALB/c BMT. (A) A20 tumors were implanted on day 0; 2 days later, 
recipients received CD8+ allo-TControl (blue circles, n = 5), CD8+ allo-TCXCR4 (red circles, n = 5), or no T cells (black triangles, n = 3). Graph shows tumor size at 
timed intervals. (B) A20.hCD34+ cells were given by intraosseous injection to the left tibia on day 0; 2 days later, recipients received CD8+ allo-TControl (blue 
circles, n = 4 day 11, n = 9 day 18), 1 × 106 CD8+ allo-TCXCR4 (red circles, n = 4 day 11, n = 9 day 18), or no T cells (black triangles, n = 2 day 18). Graphs show 
mean ± SD A20.hCD34+ accumulation in ipsilateral (left) and contralateral (right) tibia. Data pooled from 2 experiments. (C) CD8+ allo-TControl or allo-TCXCR4 
were given on day 2 (n = 5 per group); graph shows absolute numbers of CD62Lhi and CD62Llo donor CD8+ T cells on day 10 post-BMT. *P ≤ 0.05, **P ≤ 0.01 
Mann-Whitney test, 2-tailed. (D) Allo-TControl and allo-TCXCR4 (n = 7 per group), or no T cells (n = 3), were given on day 2; graph shows in vivo specific cytotoxic-
ity against BALB/c B cells on day 10 post-BMT. ND, no data. (E) A20 tumors were implanted s.c. on day 0; 2 days later, BMT recipients received no T cells 
(black triangles, n = 3), CD3+ allo-TControl (blue circles, n = 5), or CD3+ allo-TCXCR4 (red circles, n = 5). Graph shows tumor size at timed intervals. (F) Experimen-
tal design as in E. Weight ratio and histological GVHD score on day 10 post-BMT (allo-TControl, n = 13; allo-TCXCR4, n = 13; no T cells, n = 3). Data pooled from 2 
experiments. (G) On day 2, luc+ CD3+ allo-TControl or allo-TCXCR4 were transferred to BMT recipients bearing subcutaneous A20 tumors. T cell infiltration was 
monitored at timed intervals (mean ± SD, n = 3 per group). (H) Mean ± SD luc+ Treg accumulation at timed intervals within A20 tumors following cotransfer 
on day 2 in a 1:1 ratio with non-luc+ TControl (blue squares) or TCXCR4 (red squares).
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to their increased recruitment to the tumor bed. We therefore 
repeated the GvT experiments but used CD3+ T cells from B6 fire-
fly luciferase transgenic (luc+) mice to monitor the recruitment of 
allo-TCXCR4 versus allo-TControl. Following transfer of luc+ CD3+ allo-
TCXCR4 or allo-TControl to allogeneic recipients bearing A20 tumors, 
the bioluminescent signals detected from the tumor site over the 
next 16 days were similar in both groups, albeit with a small delay 
in initial recruitment of allo-TCXCR4, indicating that the greater 
antitumor effects of TCXCR4 could not be explained by enhanced 
accumulation (Figure 7G). We also tested the possibility that allo-
TCXCR4 could outcompete Tregs for limiting CXCL12-dependent 
niches within the tumor (45), by adapting the experimental design 
and cotransferring donor-strain luc+ Tregs at a 1:1 ratio with either 
TCXCR4 or TControl (both from B6 non-luc+ donors). As shown in Fig-
ure 7H, Treg recruitment to the tumor site was similar in recipi-
ents receiving either TCXCR4 or TControl. Together, these data refute 
the hypotheses that enhanced accumulation of TCXCR4 and/or out-
competition of Tregs in the tumor underpins their increased effi-
cacy. Instead, transferred TCXCR4 have greater per-cell functions 
that translate into greater antitumor immunity.
Discussion
We have demonstrated that redirection of therapeutic T cells to the 
BM confers a superior potential for expansion in vivo. Upon enter-
ing the BM sinusoids, TCXCR4 showed directed migration toward 
vascular-associated CXCL12+ cells and more efficiently compet-
ed for niches formed by IL-15Rα+ cells. Following immunization, 
TCXCR4 adopted a less differentiated memory program character-
ized by resistance to apoptosis, low expression of PD-1, and poly-
functional cytokine secretion; collectively these properties trans-
lated into a greater capacity for expansion and improved per-cell 
functions. This new strategy could potentially be used across mul-
tiple therapeutic platforms to improve engraftment, persistence, 
and functions of adoptively transferred T cells.
We found that greater competition for an IL-15Rα+–dependent 
niche in the BM underpins the superior homeostatic expansion of 
CD62Lhi TCXCR4 compared with control cells. These findings sug-
gest that TCXCR4 can preferentially occupy a BM niche or niches that 
can be saturated, which is in keeping with the known capacity of 
endogenous memory T cells to restrict BM seeding of adoptive-
ly transferred memory T cells (46). Although cellular and other 
molecular components of an IL-15α+–dependent memory T cell 
niche remain to be determined, we considered whether binding 
to CXCL12 could directly influence memory differentiation inde-
pendent of other niche elements. Recent studies have shown that 
CXCL12 stimulates the physical association between CXCR4 and 
the TCR within the immunological synapse, enhancing the recruit-
ment and phosphorylation of multiple adaptor proteins (32). In 
doing so, CXCL12 amplifies the downstream intracellular signal-
ing apparatus of the TCR (e.g., MAPK and AP-1 transcriptional 
activity), leading to increased proliferation and cytokine secretion 
(32). Furthermore, by promoting degradation of Bcl2-interacting 
mediator of death extra-long isoform (BimEL), CXCL12 costimula-
tion enhances T cell survival and promotes memory formation of 
CD4+ T cells. In this study, in vitro exposure of Ag-activated TCXCR4 
to CXCL12 did not recapitulate the phenotypic or functional prop-
erties of TCXCR4 in vivo. However, some effects of CXCL12-CXCR4 
CD8+ TCXCR4 or TControl (allo-TCXCR4 or allo-TControl) were given i.v. to 
separate cohorts of tumor-bearing mice and the antitumor effects 
compared with controls not receiving T cells. Although both CD8+ 
allo-TCXCR4 and allo-TControl exerted antitumor effects in allogeneic 
recipients compared with the no–T cell group, the efficacy of the 
TCXCR4 group was significantly greater than that of controls (Figure 
7A; median survival >42 days vs. 31 days, P = 0.004 log-rank Man-
tel-Cox test). The enhanced antitumor efficacy of TCXCR4 compared 
with controls was dependent on alloreactivity, since no difference 
between the groups was observed in syngeneic mice (Supplemen-
tal Figure 8). Similar enhancement of TCXCR4 tumor control was 
observed when the above GvT model was adapted by switching 
of the site of tumor inoculation to unilateral left-sided intrati-
bial injections of 5 × 105 A20 cells (expressing human CD34 as a 
marker, huCD34.A20) before transfer, 2 days later, of 1 × 106 CD8+ 
allo-TCXCR4 or allo-TControl i.v., or no T cells. In the intraosseous injec-
tion model, allo-TControl exerted no detectable control of local tumor 
growth in comparison with recipients receiving no T cells; in con-
trast, allo-TCXCR4 significantly delayed accumulation of A20 cells at 
this site (Figure 7B). We also observed a nonsignificant trend for 
a reduced frequency of tumor metastasis to the contralateral right 
tibia following allo-TCXCR4 infusion. To determine the phenotype of 
allo-TCXCR4 and allo-TControl following adoptive transfer to allogeneic 
BM transplant (BMT) recipients, we determined the frequency and 
absolute number of CD62Lhi and CD62Llo T cells in the BM and 
spleen at day 10. As expected, the majority of cells expanding in 
allo-TControl repertoire were CD62Llo effector T cells, with very low 
frequencies of CD62Lhi cells (median 4.7%, range 4.0%–13.7%, in 
BM, and 3.7%, range 2.9%–5.5%, in spleen). In contrast, although 
the majority of allo-TCXCR4 population also comprised CD62Llo 
effectors, we observed greater retention of CD62L expression 
(median 15.4%, range 12.3%–21.0%, in BM, P < 0.05 vs. control, 
and 9.7%, range 8.8%–15.7% in spleen, P < 0.01 vs. control; Mann-
Whitney 2-tailed). Notably, the absolute numbers of both CD62Llo 
and CD62Lhi effector T cells were higher for allo-TCXCR4 than for 
allo-TControl in spleen and equivalent in the BM (Figure 7C). These 
data indicate that transferred allo-TCXCR4 show a greater capacity 
for expansion of both effector cells as well as less differentiated 
memory precursor–like cells. Consistent with the capacity of allo-
TCXCR4 to generate functional differentiated effector cells, specific 
cytotoxic responses against allogeneic target cells were similar in 
recipients of TCXCR4 and TControl (Figure 7D).
We next considered the possibility that the enhanced fitness 
or expansion of allo-TCXCR4 could increase “on-target” toxicity 
by increasing the severity of graft-versus-host disease (GVHD). 
Because transfer of CD8+ without CD4+ allo-T cells is associated 
with only minor GVHD, we adapted the model by transferring 
1 × 105 CD3+ allo-TCXCR4 or allo-TControl i.v. on day +2. As for CD8+ 
T cells alone, CD3+ allo-TCXCR4 showed greater antitumor activity 
than control cells (Figure 7E; median survival 43 days vs. 38 days, 
P = 0.01 by log-rank Mantel-Cox test), but this was not associ-
ated with increased GVHD severity as evidenced by equivalent 
weight loss in BMT recipients of allo-TCXCR4 and allo-TControl, and 
no increase in histological GVHD (Figure 7F).
Because B cell lymphomas are enriched for CXCL12-express-
ing stromal cells (45), it was possible that the greater efficacy of 
allo-TCXCR4 in comparison with controls could be linked directly 
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We excluded the possibility that increased antitumor effi-
cacy of TCXCR4 related to enhanced trafficking to the tumor site. 
In response to hypoxia, stromal cells contained within organized 
tumors increase secretion of CXCL12, leading to enhanced 
tumor survival, neovasculogenesis, and recruitment of regulato-
ry populations (50). The lack of increased accumulation of TCXCR4 
compared with controls remained true even after correction for 
tumor size, which was different in the groups, or after transfer of 
larger numbers of T cells to exclude issues relating to the detec-
tion threshold of bioluminescent imaging (data not shown). 
Although higher expression of CXCL12 by stromal cells is report-
ed in A20 and other transplantable B cell tumors (45), a number 
of other factors (e.g., expression of other homing receptors, in 
situ proliferation) may influence the overall accumulation signal. 
Notwithstanding these factors, our data indicate increased per-
cell functions of transferred TCXCR4 compared with control cells. 
This conclusion therefore raises the question of why allo-TCXCR4 
did not cause greater GVHD than allo-TControl. One potential 
explanation is suggested by the less differentiated phenotype of 
TCXCR4 following challenge with both nominal antigen and allo-
antigen; such cells may therefore lack key effector molecules 
associated with trafficking or cytotoxic functions. Indeed, rest-
ing memory TCXCR4 lacked gene expression encoding several 
molecules such as Itga4 (51) and Gzmb (52) that are required 
for GVHD development. A non–mutually exclusive mechanism 
is that although TCXCR4 are able to egress from the BM, there is 
still an overall bias of these cells to recirculate to CXCL12-rich 
sites. Although CXCL12 is increased in the BM after irradiation 
and allo-BMT, CXCL12 expression levels in GVHD target organs 
remain relatively low (data not shown).
In conclusion, we have demonstrated that engineering of T 
cells to redirect them to the BM via CXCR4-CXCL12 increases 
their expansion and function. This innovative approach has the 
potential for multiple applications where the therapeutic efficacy 
requires long-term survival of functional T cells, for example in 
cancer or infectious disease. Further work to define the composi-
tion of the memory T cell niche in the BM in both health and dis-
ease may permit future refinement of the strategy.
Methods
Mice. C57BL/6 and BALB/c mice were purchased from Charles River 
Laboratories. B6.PL-Thy1a/CyJ (B6 Thy1.1), B6.SJL-Ptprca Pepcb/BoyJ 
(B6 CD45.1), Flk1-Gfp, and Rag1ko OT-I mice were purchased from The 
Jackson Laboratory and bred in house. Thy1.1+ C57BL/6 luciferase+ 
transgenic mice were a gift from Robert Zeiser (Freiburg University, 
Freiburg, Germany). Rag1ko, Rag1ko.Il7ko, and Rag1ko.Il15rako mice 
were a gift from Benedict Seddon (UCL, London, United Kingdom). 
UCL Biological Services bred the above mice in house; irradiated or 
immune-deficient recipients were maintained in individual ventilated 
cages. Animals used as recipients for BMT were 10–20 weeks old, and 
donors were 8–16 weeks old.
Cell lines. Ecotropic Phoenix packaging cells, used for retroviral 
particle production, were a gift from G.P. Nolan (Stanford University, 
Stanford, California, USA). The murine A20 B-lymphoblastic cell line 
has previously been described (53); in some experiments, the cell line 
was modified by pMP71 HuCD34 retroviral transduction to express 
human CD34 (A20.hCD34+) followed by isolation and sequential 
interaction may not be easily reproduced in vitro, for example, the 
modulation of T cell adhesion to the extracellular matrix and/or 
guidance of cells toward other niche elements that act in concert. 
In addition, it is also possible that the capacity of CXCR4 to form 
heteromers with other GPCRs can permit cooperative functions 
with other ligands, independent of CXCL12 (47).
Three months after antigenic exposure, the transcriptional pro-
files of resting memory TCXCR4 aligned preferentially with less dif-
ferentiated memory cells and included a number of genes known 
to be required for optimal memory generation (15, 33–37). In con-
trast to our findings following acute Ag exposure, which showed 
an initial blunting of the proliferative response, memory TCXCR4 
were enriched for gene sets relating to cell cycle and mitosis, sug-
gesting proliferative fitness in response to homeostatic cytokines. 
Although TCXCR4 demonstrated some features consistent with the 
phenotype of Tscm (15, 48) (e.g., a CD122hiBcl2hi phenotype, reten-
tion of CD62L upon antigenic challenge, and enrichment for gene 
sets linked to IL-15 and Wnt signaling), they were uniformly CD44hi, 
and expression of the stem cell marker Sca-1 was equivalent to that 
in control T cells (as opposed to the CD44loSca-1hi phenotype of 
putative murine Tscm; data not shown). Because gene expression 
analysis was not performed at a single-cell level and was confined to 
splenic T cells (in the absence of sufficient TControl in the BM for com-
parison), it is possible that resting memory TCXCR4 are in fact hetero-
geneous at the population level and that our analysis has missed 
more quiescent cells present as a minority population or at specific 
locations not sampled. In this scenario, T cells undergoing homeo-
static proliferation outnumber more quiescent Tscm-like cells that 
undergo infrequent cell divisions. In this regard, quiescent, ABC 
transporter–expressing memory T cells can be mobilized from the 
human BM using a small-molecular inhibitor of CXCR4-CXCL12 
interactions, suggesting that CXCR4-expressing quiescent T cell 
populations may normally exist at this site (21). These data reflect 
current limitations in defining core signatures for less differentiated 
memory T cells, including Tscm, and may require application of 
single-cell approaches to elucidate how repositioning of T cells to 
the BM ultimately influences cell fate.
Despite initial preferential redirection to the BM, TCXCR4 dem-
onstrated the potential to traffic to other lymphoid tissues and 
showed equivalence in accumulation within subcutaneous tumors 
and peripheral tissues during GVHD. These findings refute the 
potential concern that TCXCR4 would be trapped within the BM, 
unable to egress to sites required for therapeutic efficacy. Consis-
tent with downregulation of CXCR4 on transduced T cells upon 
transfer in vivo compared with input cells (data not shown), we 
found that gene expression signatures for GPCR signaling were 
in fact reduced in memory TCXCR4. These findings suggest that the 
overexpressed CXCR4 protein is still subject to desensitization 
following agonist binding via the physiological mechanisms of 
receptor internalization and ubiquitin-mediated degradation (49). 
This process may enable redeployment of TCXCR4 to sites other 
than the BM according to the precise stimulus in question and the 
expression of alternative homing receptors. Furthermore, the rela-
tive deficit in accumulation of TCXCR4 in the spleen and LN as cells 
initially redistributed to the BM was only transient, indicating that 
enhanced homeostatic expansion also has the potential to permit 
access of transduced T cells to other sites.
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dine (EdU) i.p., and cells were subsequently stained using the Click-iT 
Assay Kit (Thermo Fisher Scientific). Multicolor flow cytometry data 
acquisition was done with BD LSRFortessa and BD LSR II cell analyz-
ers equipped with BD FACSDiva v6.2 software (BD Biosciences). FACS 
was performed on a BD FACSAria equipped with BD FACSDiva v5.0.3 
software (BD Biosciences). All samples were maintained at 4°C for the 
duration of the sort. A minimum of 5,000 cells were collected, and only 
those with purity ≥95% were used for RNA extraction. Cells were sort-
ed directly into Buffer RLT (QIAGEN) with 1% 2-β-mercaptoethanol 
(Sigma-Aldrich), disrupted by vortexing at 3,200 rpm for 1 minute, and 
immediately stored at –80°C until further processing. Flow cytometry 
data were analyzed with FlowJo X v10 (FlowJo LLC).
Evaluation of T cell function. In vitro and ex vivo analysis of cyto-
kine generation following peptide stimulation was performed as 
described previously (56). In vivo analysis of specific cytotoxicity was 
performed as described previously (55).
Histological evaluation. Histological evaluation of GVHD in the 
skin, gut, and liver was performed single-blinded following the scor-
ing system previously described (55).
Imaging. Intravital microscopy was performed using a combined 
Zeiss LSM 780 upright confocal/2-photon microscope as described 
previously (57). Blood vessels were highlighted by i.v. injection of 8 
mg/ml 500-kDa Cy5-dextran (Nanocs). The following antibodies 
were used: anti-CXCL12 (R&D Systems) and anti-IL15RA (Abcam).
Image quantification. Microscopy data were processed with mul-
tiple platforms. Tile scans were stitched using ZEN Black (Zeiss) soft-
ware. Raw data were visualized and processed using Fiji (58). Auto-
mated cell segmentation, distance, and volume measurements were 
performed in Definiens Developer 64 using local heterogeneity seg-
mentation to isolate CXCL12+ cells. Definiens rule sets for these func-
tions were as follows: 
T cell parameters: scale, α = 8; distance to neighbor, d = 30; and 
mean intensity difference to neighborhood (MDN) threshold: 
 
    (Equation 1)
CXCL12 parameters: scale, α = 8; distance to neighbor, d = 30; and 
MDN threshold: 
    (Equation 2)
Distance measurements from this segmentation were performed 
as described previously (59). Cell tracking over time was analyzed 
using Imaris (Bitplane).
Sample preparation for gene expression analysis. RNA was extracted 
using the RNeasy Micro Kit (QIAGEN) following the manufacturer’s 
protocol. RNA yield, quality, and integrity were evaluated using the 
RNA 6000 Pico kit on an Agilent 2100 Bioanalyzer (Agilent Tech-
nologies). Cxcl12 mRNA expression in cell suspensions from the BM 
was determined as previously described (55). Amplified cDNA was 
prepared from total RNA with an Ovation Pico WTA System V2 kit 
(NuGEN) for fragmentation and labeling using the Encore Biotin 
Module kit (NuGEN), according to kit instructions, and then hybrid-
ized onto GeneChip Mouse Gene 2.0 ST arrays (Affymetrix).
Microarray analysis. Hybridized arrays were scanned with a 
GeneChip 3000 7G scanner (Affymetrix) and the image data pro-
cessed to generate .cel files. Expression Console Software version 1.4.1 
immunomagnetic enrichment using a human CD34 microbead kit 
(Miltenyi Biotec, Germany).
Retroviral vectors and transduction. The murine Cxcr4 gene was 
subcloned into a pMP71 to generate pMP71-Cxcr4-IRES-Gfp. pMP71-
IRES-Gfp was used as a control vector. Retroviral transduction was 
performed as described previously (54).
Irradiation and BM transplantation. For sublethal irradiation, mice 
received 5.5 Gy TBI. BMT was performed as described previously (55) 
with some modifications. Briefly, BALB/c mice (or B6 mice for syn-
geneic BMT controls) received lethal irradiation (4 Gy twice over 72 
hours) before i.v. infusion of 5 × 106 T cell–depleted B6 BM. On day 2 
following BMT, mice were inoculated with 5 × 105 A20 cells s.c. into 
the flank or with 5 × 105 A20.hCD34+ by intra-bone injection into the 
left tibial BM cavity during anesthesia. Tumors were allowed to grow 
for 2 days before i.v. injection of B6 allo-TCXCR4 or allo-TControl. Mice 
were scored for clinical severity and weight 3 times per week or more 
frequently if necessary, and were sacrificed according to a predefined 
severity endpoint, or if tumor surface area was greater than 200 mm2 
or developed surface ulceration. For tumor survival experiments, 
tumors greater than 150 mm2 were categorized as an event. Biolumi-
nescent imaging of firefly luciferase+ T cell infiltration of tumors was 
performed as described previously (54).
Prime-boost vaccination. Isolation of CD8+ T cells or CD11c+ DCs 
was performed by immunomagnetic selection from splenocytes using 
Manual MACS Cell Separation Technology (QuadroMACS Separator, 
LS columns, CD8a [Ly-2] and CD11c MicroBeads; Miltenyi Biotec), 
according to the manufacturer’s instructions. For in vitro experiments, 
SIINFEKL peptide (Invitrogen) was added at a concentration of 5 μM. 
In competitive in vivo experiments, 5 × 105 to 1 × 106 each of TCXCR4 and 
TControl were mixed into a 1:1 ratio before injection, and vaccination was 
performed at 24 hours and on day 29 by s.c. injection of 200 μM SIIN-
FEKL or an irrelevant peptide in a 1:1 ratio with incomplete Freund’s 
adjuvant (Sigma-Aldrich). Alternatively, mice received 1 × 106 CD11c+ 
peptide-loaded DCs intravenously.
Isolation of murine immune cells. To prepare cell suspensions from 
spleens and lymph nodes, the freshly removed organs were mashed 
and passed through a 40-μm cell strainer; red blood cells were 
removed by isotonic lysis with ammonium chloride (ACK Lysing Buf-
fer; Lonza). Cells were resuspended in FACS buffer (PBS, 2% FCS, 
2 mM EDTA; Lonza) for counting and immunolabeling. To isolate BM 
cells, both epiphyses of the long bones of the hind limbs were cut, and 
the BM was flushed out with FACS buffer. The cell suspension was fil-
tered through a 40-μm cell strainer, and red blood cells were removed 
by isotonic lysis with ammonium chloride. Cells were resuspended in 
FACS buffer for counting and immunolabeling.
Flow cytometry. The following monoclonal antibodies were used 
for flow cytometry: anti–murine CXCR4 (clone 2B11), CD8a (clone 
53-6.7), CD62L (clone MEL-14), CD127 (clone A7R34), CD122 (clone 
TM-β1), CD132 (clone TUGm2), CD45.2 (clone 104), TNF-α (clone 
MP6-XT22), IL-2 (clone JES6-5H4), Bcl2 (clone 3F11), and active cas-
pase-3 (clone C92-605) (all supplied by BD Biosciences); and anti–
murine Thy1.1 (clone H1S51), CD44 (clone IM7), CD25 (clone PC61), 
CD45.1 (clone A20), IFN-γ (clone XMG1.2), Eomes (clone Dan11mag), 
PD-1 (clone RMP1-30), and KLRG-1 (clone 2F1) (all supplied by eBio-
science). For intracellular staining, cells were fixed and permeabilized 
with BD Cytofix/Cytoperm (BD Biosciences). For measurement of 
proliferation, animals were injected with 100 μg 5-ethynyl-2-deoxyuri-
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Study approval. All procedures were conducted in accordance 
with the United Kingdom Home Office Animals (Scientific Proce-
dure) Act of 1986, and were approved by the Animal Welfare and 
Ethical Review Bodies at UCL (Royal Free Campus, London, United 
Kingdom) and Imperial College London (South Kensington Campus, 
London, United Kingdom).
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(Affymetrix) was used to generate quality control statistics for each 
sample; only the samples that passed quality control were included 
in the analysis. Raw sample expression signals were background-
subtracted and quantile-normalized, and the probe-level data were 
summarized using the Robust Multi-array Average algorithm (60, 61) 
implemented in the oligo BioConductor R package (62). Transcripts 
identified through multiple probes were collapsed based on maximum 
expression values using the CollapseDataset module of GenePattern 
software (Broad Institute) (63).
Differential gene expression. The limma BioConductor R package 
was used to perform analyses of gene differential expression, using an 
empirical Bayes moderated t statistic corrected for multiple-hypothesis 
testing using the Benjamini-Hochberg procedure, with a cutoff of 
ANOVA P value ≤0.01, and an absolute fold-change cutoff of ≥1.5.
Gene set enrichment analysis. Gene set enrichment analysis (GSEA) 
was performed using the GSEA software with the gene sets derived 
from the Reactome pathways database collected in the Molecular Sig-
natures Database (MSigDB v5.1, Broad Institute), and the gene sets 
identified by Best et al. (42), Yang et al. (43), and Hurton et al. (44).
Statistics. Apart from microarray data, which were analyzed with 
the aforementioned programs and methodologies, statistical analy-
sis was performed using GraphPad Prism version 6.00 for Mac OsX 
(GraphPad Software). Summary data are shown as either box-and-
whisker graphs (showing median, 25th, and 75th centiles and mini-
mum/maximum values) or means ± SD and individual replicate data. 
Significance was assessed using a 2-tailed Mann-Whitney U test or a 
2-tailed Wilcoxon’s signed-rank sum test for paired comparisons of 
nonparametric data. Survival curve comparison was performed using 
the log-rank Mantel-Cox test. P less than or equal to 0.05 was taken to 
indicate a significant difference between groups.
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